title: Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
abstract: Despite many treatment advances, metastatic breast cancer remains an incurable disease and is the third leading cause of cancer-related deaths in Europe. Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination. Hand-foot syndrome and diarrhoea are the most frequently reported side effects, while capecitabine-related ileitis is very rare. Deficiency of dihydropyrimidine dehydrogenase activity leads to severe toxicities after administration of 5-fluorouracil or its prodrugs. We report two cases of patients with metastatic breast cancer who developed ileitis after treatment with capecitabine. One patient had a DPYD gene abnormality.
authors.affiliation: Institut Jules Bordet, Brussels, Belgium.
authors.forename: Maha
authors.initials: M
authors.lastname: Mokrim
authors.forename: Philippe G
authors.initials: PG
authors.lastname: Aftimos
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
authors.forename: Martine
authors.initials: M
authors.lastname: Piccart-Gebhart
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000069287:Capecitabine; D044584:Carcinoma, Ductal / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D003092:Colitis / Q000175:diagnosis; D000075202:Contraindications; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D003937:Diagnosis, Differential; D003967:Diarrhea / Q000139:chemically induced / Q000175:diagnosis; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000150:complications; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007079:Ileitis / Q000139:chemically induced*; D009154:Mutation; D009362:Neoplasm Metastasis; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil
references.citation: Clin Colorectal Cancer. 2004 Sep;4(3):181-9
references.pmid: 15377401
references.citation: Clin Colorectal Cancer. 2006 Jan;5(5):359-62
references.pmid: 16512996
references.citation: Oncologist. 2012;17(4):476-84
references.pmid: 22418569
references.citation: Clin Cancer Res. 2011 May 15;17(10):3455-68
references.pmid: 21498394
references.citation: Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9
references.pmid: 22997442
references.citation: Oncologist. 2005;10 Suppl 3:20-9
references.pmid: 16368868
references.citation: Ned Tijdschr Geneeskd. 2011;155:A3064
references.pmid: 21486509
references.citation: Oncologist. 2006 Apr;11(4):325-35
references.pmid: 16614228
references.citation: J Oncol Pharm Pract. 2006 Sep;12(3):131-41
references.pmid: 17022868
references.citation: Ann Saudi Med. 2012 Nov-Dec;32(6):661-2
references.pmid: 23396034
references.citation: J Clin Oncol. 2002 Jun 15;20(12):2812-23
references.pmid: 12065558
references.citation: Case Rep Med. 2012;2012:154981
references.pmid: 23251164
references.citation: Lancet Oncol. 2005 Mar;6(3):158-66
references.pmid: 15737832
references.citation: Ann Oncol. 2009 Nov;20(11):1771-85
references.pmid: 19608616
references.citation: Clin Colorectal Cancer. 2009 Oct;8(4):231-4
references.pmid: 19822515
references.citation: Cancer Pract. 2001 Nov-Dec;9(6):283-9
references.pmid: 11879330
references.citation: Curr Opin Oncol. 2013 May;25(3):296-304
references.pmid: 23493191
references.citation: Clin Ther. 2005 Jan;27(1):23-44
references.pmid: 15763604